Life sciences industry faces rising tide of taxes

For years multi-national pharma companies have enjoyed a relatively stable tax rate. Now PriceWaterhouseCoopers says that as personalized medicines grow in importance, the life sciences industry will become more service-oriented, adding diagnostics and new patient compliance technology that is likely to drive a rise in their overall tax rate -- a trend that could have serious consequences for the biotech companies Big Pharma partners with to develop a new generation of biologics. Report

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.